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imply stated, for personalized medicine to
become a hallmark of mainstream modern medicine, the
attributes of precision and meaningful improvement in
quality of health care through technology and informa-
tion management must be obvious and unequivocal.
Throughout biomedical science, there has been much
anticipation of the potential impact of genomic, molec-
ular, and personalized medicine for health. The begin-
ning of 21st-century biomedical research was heralded
by the completion of the Human Genome Project, which
gave a great deal of momentum to new capabilities of
science and technology in the hands of medical practi-
tioners and the public. 
Across the spectrum of clinical neurosciences, many
advances are clearly being made toward understanding
the biological underpinning of disease. Applications of
new technology platforms in research are widely seen in
neurodegenerative disorders, neuropsychiatric condi-
tions, addiction, and developmental disorders. While the
impact of translation of these new research frontiers will
likely take many years to be measured, pressing impli-
cations requiring important policy considerations are vis-
ible today. 
Significant innovation and technological achievements
lie at the heart of the rapid pace of accrual of scientific
information to support personalized medicine. Dramatic
decreases in cost and increases in analytical throughput
have placed within reach the possibility of sequencing a
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Remarkable advances in the fundamental knowledge
about the biological basis of disease and technical
advances in methods to assess genomic information have
led the health care system to the threshold of personal-
ized medicine. It is now feasible to consider strategic
application of genomic information to guide patient
management by being predictive, preemptive, and pre-
ventive, and enabling patient participation in medical
decisions. Early evidence of this transition has some hall-
marks of disruptive innovation to existing health care
practices. Presented here is an examination of the
changes underway to enable this new concept in health
care in the United States, to improve precision and qual-
ity of care through innovations aimed at individualized
approaches to medical decision making. A broad range
of public policy positions will need to be considered for
the health care delivery enterprise to accommodate the
promise of this new science and technology for the ben-
efit of patients.  
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 377person’s entire genome for $1000. Broad applications of
genomic characterization of disease states in the phar-
maceutical, biotechnology, and diagnostic research sec-
tors have become mainstays of early- and late-stage
therapeutic development. Despite the robust invest-
ments in discovery research technologies to exploit
genomic variation of disease-related genes, personalized
approaches to disease management have raised chal-
lenges for industry because of the potential segmenta-
tion effect on diminishing the potential marketable pop-
ulation for new medical products. Nevertheless, there
remains strong interest among pharmaceutical and
biotechnology developers for clinical strategies to
employ diagnostic tests in combination with therapeutic
interventions. Whether this “codevelopment” approach
will be widely employed by industry to enhance clinical
development strategies, or is engaged in the clinical prac-
tice regimen as a personalized medicine tool, is largely
unknown. The pathway toward large-scale use of mole-
cular diagnostics in managing therapy decisions has sub-
stantial obstacles and misaligned incentives that will
require significant policy modifications before person-
alized medicine becomes commonplace in health care.
1
While today’s view of the horizon for many aspects of
clinical practice remains unclear, some disciplines of
medicine, such as oncology, are rapidly adopting clinical
genomic analysis and individualization of therapies.
Some of the more relevant challenges are not the scien-
tific validity of the use of genomic tools, but rather the
capability to deploy and organize information in mean-
ingful ways in clinical practice. In addition, it is impor-
tant to recognize that all of the discovery research and
technological advancement is occurring in a highly
volatile climate of change in health care policy. Access
to health care, public financing of health care services,
moving away from fee-for-service reimbursement mod-
els, comparative effectiveness research, changing focus
on preventive health services, looming financing chal-
lenges accompanying dramatic shifts in demographics of
aging populations, and continued concerns regarding
security and privacy of health information are all part of
today’s policy framework, representing a cauldron of
change in health care. 
In this overview, the policy perspective of the translation
of genomic science into health care practice is examined
under the moniker of personalized medicine. The focus
through this lens addresses how advances in science,
technology, and health care in the United States come
together while recognizing that global influences in all
of these domains are increasingly relevant to the domes-
tic picture. Currently, personalized medicine addresses
two general advanced technology platforms; molecularly
targeted therapeutics which are selective for a specific
biological marker (biomarker—defined as a character-
istic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention
2), and molecular diagnostics. The latter, rel-
ative to the neuroscience areas, can generally be consid-
ered to include genomic diagnostic tests, biobehavioral
testing measures, and imaging technologies. While rec-
ognizing the value of the contribution of many advanced
imaging technologies to drug discovery and develop-
ment and clinical disease state assessment, this report is
principally focused on genomic diagnostic technologies.
Currently, three broad medical applications of these
technologies are most frequently considered as person-
alized medicine approaches: to determine likelihood of
clinical response with molecularly targeted agents, to
determine polymorphisms likely to contribute to adverse
events or subtherapeutic response to drugs, and to assess
disease biomarkers as predeterminants for diseases and
conditions, such as heart disease, neurodegenerative dis-
orders, and cancer. 
In 2006, the US Department of Health and Human
Services (HHS) initiated a federal effort to coordinate
and facilitate steps across the agencies to establish path-
ways to enable genomic and personalized medicine to
enter health care. In recognizing potential obstacles that
predictive, preventive, and pre-emptive approaches to
health care may face, the Personalized Health Care
Initiative was launched to avoid unnecessary delays and
develop effective communication strategies for the
intended use of these technologies in health care. The
framework for this initiative was built on two funda-
mental tenets: that linkage of clinical and genomic infor-
mation would yield insights into human health and dis-
ease, and that the information gained from this linkage
would be used, and not misused, to benefit patients and
consumers.
3 Recently, HHS published a report that
included an analysis of health systems changes that were
being undertaken in various institutions and through col-
laborative projects.
4 The report also looked at the need
for changing roles of key stakeholders in successful
transformation of services in health care, required to suc-
cessfully implement personalized medicine practices.
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issues associated with personalized medical care and
some of the solutions to overcome them. 
Definitions and context of 
personalized medicine
The use of the term “personalized medicine” in the lit-
erature predates the advances in clinical genomics that
have advanced the biological understanding of differ-
ences between individuals. Applications of this termi-
nology were often related to customized behavioral
approaches to management of health conditions. Prior
to the 1990s, the use of the term “personalized medicine”
was used to imply that there were sociological, educa-
tional, and psychological bases for alternative
approaches to patient management that led to more or
less successful practices. In the late 1990s, somewhat
simultaneously with the approaching completion of the
Human Genome Project, more common usage of the
term reflected genetic understanding for differences in
pharmacotherapy, ie, pharmacogenomics. This also coin-
cided with the market entry of several molecularly tar-
geted therapies in oncology that used genetically based
determinants for the development and subsequent clin-
ical application of novel therapeutic agents. Trastuzumab
(Herceptin®), a monoclonal antibody that serves as a
treatment for breast cancer, has often been heralded as
the first molecular therapy ascribed to personalized
medical applications through the use of an assay to
detect overexpression of the Her2 protein, thereby iden-
tifying patients who are most likely to respond. 
Since then, there have been many interpretations and
contexts applied to the term “personalized medicine.”
For the purposes of this discussion, the definition used
here will be based on one by Willard et al as “the deliv-
ery of health care in a manner that is informed by each
person’s unique clinical information; genetic, genomic,
and other molecular biological characteristics; and envi-
ronmental influences. The goals of personalized medi-
cine are to take advantage of a molecular understanding
of disease, combined with other individual factors, to
optimize preventive health care strategies while people
are still well or at the earliest stages of disease.”
5
Increasingly, consumer interactions with the health care
system and engagement in proactive participation in
agenda setting and decision making are being applied to
new ends. The rise of advocacy organizations and their
involvement in therapeutic development, application of
social networking enterprises for patient connectivity (ie,
PatientsLikeMe), greater involvement of public members
in policy development, and growing public influences on
coverage and reimbursement policies add new context to
patient advocacy. Greater public awareness and growing
understanding of personal utilities afforded by informa-
tion technology, genomic analysis-assisted disease risk
assessment, and computer-assisted living devices all bring
a broader context to this discussion, which is referred to
here as personalized health care (as distinguished from
medical context of diagnosis and interventions).
6
While much of the emphasis in discussions about per-
sonalized medicine has been focused on medical tech-
nologies, aspects of information technology are becom-
ing their equal in enabling individualization or mass
customization of health care schemes. This is not unlike
the disruptive innovation qualities that computers have
had in other industries, and will likely lead to wide-rang-
ing and equally disruptive change for the medical com-
munity.
7 One key characteristic of change will be the
blurring of the lines between the established medical
community, the patient/consumer, and other community
members “linked” by information systems. In the future,
personalized health care will represent an amalgam of
patient experiences that will be customized, interactive,
less episodic in nature, and more of a continuum of care.
There will be many challenges ahead, in order for this
model to be accepted and demonstrated to provide a
higher quality of care, greater understanding by patients
of their condition and health care choices, and improved
efficiency and effectiveness of health care practices. 
Key catalysts on the pathways 
to personalized medicine
The pace at which discovery research in human genomics
enters translational research may be a trajectory unlike
past novel interventions. In looking at personalized med-
icine through the lens of clinically meaningful impact, it is
worthwhile to provide a context for some of the forces at
play in creating the foundation for personalized medicine. 
Genomic sequencing and related analytic platform
technologies
The establishment of the public domain as the key refer-
ence source for the Human Genome Project opened the
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in advancing scientific frontiers. Additionally, the substan-
tial investments in large-scale science included funding for
technology platforms and their applications in the project
itself. As a consequence, there was a surge in the develop-
ment of sequencing technologies yielding remarkably
higher throughput, dramatically reduced costs, and greatly
enhanced analytic capabilities. Government-supported
incentives for technology development created an eco-
nomically feasible environment that has expanded
genome-scale research capabilities from large sequencing
centers to the laboratory bench, and now, virtual discovery
research through computational analysis. These efforts
were first engaged to sequence targeted regions of the
genome, in order to understand polymorphisms in genes
and their contribution to genetic disorders. The HapMap
project, by building a widely diverse international public
genome database, rapidly accelerated the capability to
compare population-based genetic makeup, resulting in
highly annotated databases of disease genes.
8 Evolutionary
aspects of genomic information for understanding biolog-
ical diversity came in the form of sequencing projects of
other species. These projects yielded tremendous public
resources that enabled biological understanding to be
gained in model organisms, leading to broader insights into
human development and disease mechanisms. 
Advances in genomic information were not based solely
on high-throughput sequence analysis. The development
of microarray technology enabled ease of use for per-
forming hybridization analysis on virtually any laptop
computer. A new basis for diagnostic tests has been pro-
vided by the vast amount of gene expression data now
available through large-scale measurement of mRNA
abundance. The platform greatly expanded the capabil-
ities to include comparative analysis of specimens for
gene expression and the volume of genomic data that
could be generated in hours of experimental time.
Coupled with the development of analytical software,
scientists are now armed with an adaptable platform to
evaluate polymorphisms, compare the effects of inter-
ventions on DNA analysis, and ultimately evaluate phar-
macologic impact on gene expression. Over the past 5
years, gene expression profiling has become a commonly
used quantitative method in molecular and systems biol-
ogy. In a short period of time, this technique has also
become a common translational research tool widely
applied in clinical medical laboratories, particularly in
oncology for assessment of tumor biomarkers. 
Genomic analysis platforms have had dramatic impact
on clinical research and therapeutic research and devel-
opment, and spawned a broad range of molecular diag-
nostic assays and devices. Meanwhile, medical applica-
tions remain unclear, as the clinical experience and
evidence is lacking for many potential uses.
Pharmacogenomics is viewed by many as a discipline of
clinical pharmacology which deals with the influence of
genetic variation on drug response in patients by corre-
lating gene expression or single-nucleotide polymor-
phisms with a drug's efficacy or toxicity. By doing so,
pharmacogenomics provides a rational means to opti-
mize drug therapy with respect to the patients' genotype,
to ensure maximum efficacy with minimal adverse
effects. This approach sets the stage for personalized
medicine, in which drugs and drug combinations are
optimized for each individual's unique genetic makeup.
The clinical impact of this has been primarily recognized
in the alteration of many drugs' biotransformation pro-
files as a result of polymorphisms that contribute to slow
or rapid metabolism. These manifestations are relevant
to a broad range of pharmaceuticals, leading to either
subtherapeutic responses in the case of enhanced activ-
ity of drug metabolizing enzymes, or adverse events
from toxicologic manifestations of slowed drug inacti-
vation. These studies have led to implications by the US
Food and Drug Administration (FDA) to notify pre-
scribing clinicians that pharmacogenomic testing may be
of value in dosing and therapeutic selection, in some
cases. The FDA maintains a list of drugs with labeling
requirements that under some circumstances require
pharmacogenomic testing of subpopulations for poly-
morphisms before the drug is prescribed.
9,10
Analysis of pharmacogenomic data has become a sub-
stantial undertaking by the FDA. Among these steps in
developing the translational science for the future, the
FDA, together with the pharmaceutical industry and
academic investigators, has established a voluntary data
submission process to enable better understanding of the
interaction of developmental therapies with genes and
their clinical manifestations.
11Arguably, the largest num-
ber of patients with potential clinical application of a
pharmacogenetics test under consideration in medical
practice today are those who will be prescribed the anti-
coagulant warfarin. Several polymorphisms lead to the
abnormal metabolism of the drug, which has a narrow
therapuetic index fraught with medical complications.
Research continues on the clinical importance of routine
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involved in warfarin metabolism, and variants in Vitamin
K epoxide reductase (VKORC1). Several commonly used
drugs for neurologic conditions have FDA labeling for
pharmacogenomic implications. Carbamazepine-related
Stevens Johnson syndrome has been linked to polymor-
phisms in the HLA B haplotype. Individuals carrying
one or two *1502 alleles are advised to avoid carba-
mazepine. Labeling for pharmacogenetic assay consid-
eration is also present for fluoxetine and other selective
serotonin reuptake inhibitors (SSRIs) metabolized by
Cytochrome P450 2D6.Abnormal clinical response may
occur due to aberrant drug metabolism, and genetic test-
ing may yield useful information to aid in dosing para-
meters.
12A commercially available microarray has been
developed and FDA approved for use to assist in deter-
mining Cytochrome P450 polymorphisms, and other clin-
ical laboratory tests are used in a variety of settings for
consideration in drug dosing.
13
Nonpolymorphic genetic modifications are increasingly
being applied to understand gene-environment interac-
tions in diseases and clinical conditions. Further expan-
sion of the capabilities of microarray technology has
enabled genomic analysis at additional levels by mea-
suring DNA methylation and histone modification.
14 In
addition, analysis of copy number is providing insight
about genomic variation beyond nucleotide polymor-
phism, showing significance in the etiology of cancer,
atherosclerotic heart disease, and complex neurological
conditions such as Alzheimer’s disease and schizophre-
nia.
15,16Although not as commonly applied in the clinical
laboratory as expression profiling, these methods are
showing promise in therapeutic research and develop-
ment and translational research genomic analytical lab-
oratories. 
Clinically meaningful laboratory applications in the
future will need to overcome significant barriers.
Currently, there are not widely accepted methods and
standards for performing genomic analysis using array
platforms. There is also wide variation in the analytical
and computational methods used in comparative
genomic analysis. In addition, there is a paucity of stan-
dardized control biomaterials for use in analyses. Finally,
all of these quantitative measures are highly sensitive to
clinical specimen acquisition, preparation, and storage
methods. Little comparative work on standards for con-
trols and disease biospecimens has been done on estab-
lishing normal datasets for gene expression methods.
Recently, a summary of these issues was addressed
through a guidance document issued by the Centers for
Disease Control and Prevention (CDC).
17 The lack of
highly annotated and fully characterized biospecimens
with longitudinal phenotypic and demographic infor-
mation remains a significant barrier for all of transla-
tional research in personalized medicine, but is most
notable in large-scale genomic analyses.
18
The application of the various genomic technology plat-
forms has led to transformative research in population
genetics. Over the last several years, population-based
research studies, such as the Framingham Heart Study,
have enabled large-scale genomic analyses from clinical
resources. Collectively, these genome-wide association
studies (GWAS), have enabled cross-study analyses
from publicly available databases known as dbGAP
(database of genotype and phenotype).
19 Over the past
several years, hundreds of new GWAS results have
yielded insights into multigene effects to a wide variety
of human diseases and conditions. Many of these new
mutations are identified in noncoding regions.
Collectively, the discovery of these new associations is
prompting more hypothesis generation about disease
pathways than generating platforms for new diagnostics
and therapeutics. These public resources are proving to
be useful discovery resources for various disease areas,
such as psychiatry, enabling consortia of investigators to
use statistical analytic methods to map genetic architec-
ture of common disorders.
20
Information technologies in health care and impact on
personalized medicine
A key infrastructure needed to establish a medical prac-
tice environment for individualized decision making is a
robust and facile information technology capability. The
reasons for this are the dependency on key attributes
about the patient’s health status, detailed data needs for
phenotypic characteristics, and the complexity of the
types of analytical data and decision algorithms that will
be used to support more precise, preferred, and predic-
tive health outcomes for the patient. 
Much of the advances in genomic research have been
supported by computational studies that have enabled
large databases to be assembled with highly contextual-
ized data to develop associative information about the
relation of genes and biology. While technological
advances in capacity for sequencing analysis have
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Moore’s Law, there is no doubt that this success has been
largely tied to computational advances. 
The transfer of this knowledge from the laboratory to
the health care setting faces a steep climb to establish
information management practices in the US. Improved
clinical knowledge from research is highly dependent on
recovering standardized, useful clinical information from
medical practice. The delivery of knowledge in clinically
useful formats to support decision-making processes is
similarly critical. The information management needs to
span these gaps is found in the electronic health infor-
mation technology (health IT). The major components
of a health IT system to support personalized medicine
includes widely used electronic medical record systems
and personal health records that consumers can use for
recording their own health care information. A second
component is a nationwide effort to enable health infor-
mation exchange among health care providers and insti-
tutions that will enable portability of information to suit
purposes on demand. A third element includes elec-
tronic decision support capabilities that engage medical
records systems to facilitate evidence-based health care
choices by the health care provider. Collectively, these
are dependent on data standards that enable semantic
and syntactic interoperability of data across health IT
systems. As a health care enterprise, the US has a dearth
of electronic information to support these needs, and it
will take many years to achieve all of these steps to ben-
efit all patients. The inability to connect information
sources is a major contributor to the high costs of clini-
cal research, particularly clinical trials. Despite escalat-
ing health care costs and substantial service inefficien-
cies in the US, there has been little incentive until
recently to make capital investments in information sys-
tems for the inpatient and ambulatory care setting. 
Today, less than 20% of all physicians use electronic
health record systems, and far fewer have systems that
provide decision support capabilities to aid personalized
medicine. Some progress is being made on the require-
ment for electronic transmission of prescriptions from
the health care provider to the pharmacy. Computerized
physician order entry (CPOE) for ordering laboratory
tests and other services has also been improving. As part
of the American Recovery and Reinvestment Act of
2009, nearly $20 billion will be invested in the next sev-
eral years to build health IT capacity through network
capabilities, support acquisition of electronic systems by
practice groups and health care institutions, and provide
fiscal incentives for adoption and use of health IT sys-
tems.
21
The ability to harness clinical information and use it for
research applications will be crucial for personalized
medicine to benefit from these national investments.
Paramount for patients is the knowledge that their infor-
mation will be handled securely, that their privacy in
health matters will be protected, and that the confiden-
tiality of this information is respected. Altogether, for
personalized medical practice to flourish and provide
meaningful value, a health information exchange system
must be developed that enables information to be
mobile, standards-based, and support evidence-based
medical care practices. The yield from this will be greater
use of health care provider resources, more precision
and predictability in medical choices, and provision of
patients with more information and choices to address
their needs. 
Public databases and data access 
One of the key facets enabling the rapid entry of
genomic information into clinical application is the pol-
icy framework that underpinned the dissemination of
research information. The public aspects of federally
funded research did not stop with the completion of the
human genome project. While the early part of this
decade led to the birth of commercial entities that build
genomic databases, the avenues of public information
resources continued to evolve. A series of policies led
major science and medical journals to require submission
of newly discovered gene sequences into GenBank. This
process of openness continued with establishment of
additional databases requiring transparency of research,
enabling resources to be used for new discovery rather
than replication of results. One of the key building blocks
for establishing the base for personalized medicine and
the rapid advances of genomic research was built on fun-
damental public access policies initiated in the 1990s. In
1996, free Internet access to the National Library of
Medicine Medline holdings of scientific information
rapidly accelerated the dissemination of new science. The
National Center for Biological Information added
immense public databases of genomic information, imag-
ing repositories, and many other resources that support
the translation of research into medical applications.
Further advancing this is a policy implemented in 2008
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made publicly available within 12 months of publication.
22
PubMed Central, an open-source digital information
resource, was established in February 2000 and has been
followed by additional open-source publication venues.
The net yield of these public policy efforts was to make
biological information more readily available and accel-
erate the application of discovery research into clinical
and translational research. While it is difficult to quantify
the impact of public policies on the openness of scientific
information, the effects have been widespread. Lowering
barriers to commercial sector technology development,
increasing the diversity of scientific collaborations, and
enabling global research collaborations through the open
language of science have been important steps to accel-
erate the arrival of personalized medicine. 
Taken together, the profound advances in informatics
platforms, allowing large and complex data to be moved
rapidly, coupled with computational capabilities for
gleaning meaningful associations of biological systems,
have been transformative. Policies promoting sharing
and dissemination of information have had a similar
impact on accelerating the pace of science. 
Vocabulary standards
The Human Genome Project brought with it a key
aspect of data standards guiding the vocabularies of
genetic information. The requirement to use interna-
tionally accepted common data elements for gene
nomenclature and reference sequence information has
provided specificity and avoided (to a large degree) con-
fusion about the meaning of scientific data. Structuring
digital biology to conform to unified modeling language
(UML) has enabled genomic information to be modeled
across all domains of scientific application through
genomic standards, which has aided in the translation to
clinical application. Standard clinical nomenclature is
now being widely accepted for genomic test information.
Health Level 7 (HL7), Online Mendelian Inheritance in
Man (OMIM), Logical Observation Identifiers Names
and Codes (LOINC), and Systematized Nomenclature
of Medicine (SNOMED) provide widely accepted stan-
dards for clinical definitions, including disease and con-
dition terminology, laboratory test information, and
other terms for health care practices. Highly annotated
clinical reference repositories for standards have been
developed including the National Cancer Institute
repository of data elements caDSR (cancer data stan-
dards registry and repository). The caDSR is a database
and a set of Application Programming Interfaces (APIs)
and tools used to create, edit, control, deploy, and find
common data elements (CDEs) for metadata consumers
and for UML model development.
23
Protection of civil rights regarding genetic information
On May 21, 2008, the US framework of civil rights was
enhanced through the signing into law of the Genetic
Information Non-discrimination Act of 2008 (GINA).
24
This legislation was long sought on behalf of public
interest, as the absence of federal regulations to prohibit
use of genetic test information in employment decisions
and provision of health insurance benefits on the basis
of inherited traits was a deterrent for individuals to par-
ticipate in research studies. Together with the Health
Insurance Portability and Accountability Act provisions
(HIPAA), GINA generally prohibits health insurers or
health plan administrators from requesting or requiring
genetic information of an individual or an individual’s
family for decisions regarding coverage, rates, or preex-
isting conditions. The law also prohibits employers from
using genetic information for hiring, firing, or promotion
decisions, and for any decision regarding terms of
employment. Importantly, the statute provides defini-
tions regarding the consideration of genetic test and its
application under GINA. 
Regulatory oversight of genetic testing
In the US, the proliferation of genetic tests has raised
awareness about a dichotomy in the regulatory frame-
work across technology platforms and the federal agen-
cies that oversee them. Molecular diagnostics that are
performed in a laboratory as a laboratory-developed test
are overseen by federal regulations issued under the
Clinical Laboratory Improvement Act of 1972 (CLIA)
that addresses the analytical validity of the testing pro-
cedures. Analytical validity of a genetic test defines its
ability to accurately and reliably measure the genotype
of interest. Examples of common tests of this type
include cytogenetic studies, immunohistochemical analy-
ses, and fluorescent in situ hybridization assays per-
formed by clinical reference laboratories. 
Molecular laboratory assays that are assembled and
marketed as “kits” are medical products reviewed by the
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validity of a genetic test defines its ability to detect or
predict the associated disorder or phenotypic presenta-
tion. In this scenario, kits such as the polymerase chain
reaction assay can be used in a clinical setting that may
be outside of the clinical reference laboratory. The FDA
review of these assay kits is considered a medical prod-
uct under regulations of devices. In recent years, there
has been much discussion regarding the different path-
ways that genomic assays may be brought into the clin-
ical market based on the oversight of laboratory tests.
Much of this discussion has been centered on a subset of
clinical tests known as in vitro diagnostic multivariate
index assays (IVDMIA) that integrate the analysis of
multiple genes on technology platforms, providing an
index score as a result. The mathematical algorithms that
reflect the integration of these various gene expressions
or polymorphisms are based on clinical population stud-
ies that associate the interaction of various genes under
different clinical scenarios. Today, IVDMIA are used in
guiding treatment decisions in breast and colon cancer,
and providing clinical guidance regarding likelihood of
recurrence under various treatment regimens. These
tests are performed in clinical reference laboratories and
are not subject to FDA review. A draft guidance has
been issued that proposes that manufacturers of 
IVDMIA obtain premarket approval. Recognizing that
the potential for a large number of complex genetic tests
will be coming into the clinical marketplace in the near
future, the Secretary of Health and Human Services
requested a review of the federal oversight of genetic
tests. The Secretary’s Advisory Committee on Genetics,
Health, and Society issued a comprehensive report in
April 2008 that highlighted the impediments to data sup-
porting medical use of genetic tests and recommended
steps to improve the oversight process.
25
Policy issues regarding clinical utility and medical 
benefit from the use of genetic tests
Beyond the regulatory review of medical products, the
integration of personalized medicine technologies into
clinical practice also requires coverage and reimburse-
ment of costs of the tests by health care insurance
providers and other organizations that pay for health
care services. A centerpiece of these considerations is the
evidence that supports genetic test information adding
value to the medical care experience. The clinical utility
of a genetic test defines the elements that need to be
considered when evaluating the risks and benefits asso-
ciated with its introduction into routine practice. Overall,
the framework for supporting coverage and reimburse-
ment decisions for genetic tests has been hampered by
the lack of substantive clinical data to demonstrate con-
firmed value for their use in health care. The lack of a
clinical trial infrastructure for diagnostic assays, similar
to that for drugs and biologics, has made demonstration
of clinical utility and medical effectiveness difficult to
demonstrate. For personalized medicine applications,
economic issues play some part in the inability of small
diagnostic companies or reference laboratories to per-
form randomized clinical trials to show benefit by the
determination of medical intervention on the basis of
treatment outcome. 
One suggested framework for considering the compos-
ite evidentiary needs for genomic tests identifies impor-
tant information needs for medical use.
26,27 In 2004, the
Centers for Disease Control and Prevention (CDC) ini-
tiated a program to systematically review the clinical evi-
dence supporting applications of genetic tests. The pro-
gram, known as the Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) con-
ducts systematic, evidence-based process for assessing
genetic tests and other applications of genomic technol-
ogy in the transition from research to clinical and public
health practice.
28 Through this program, CDC supports
evidence evaluations through literature reviews. One of
the first studies conducted involved the use of pharma-
cogenetic testing of Cytochrome P450 polymorphisms in
patients being prescribed SSRIs. The evidence review
concluded, as it has for a variety of other genetic tests,
that there was insufficient data to support routine use of
genetic testing.
29 Multiple other studies have been con-
ducted to examine other genetic tests and similar find-
ings were noted. This pattern suggests that to fully inte-
grate genetic testing practices into health care,
substantially more clinical research is needed to demon-
strate clinical utility. 
Health care financing considerations about coverage
and reimbursement of genomic tests
The Centers for Medicare and Medicaid Services (CMS)
recently deliberated on the coverage and reimbursement
of pharmacogenomic testing. Coverage decisions regard-
ing new health technologies under Medicare can be han-
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by petitioning authorization by the sponsor to a regional
Medicare contractor, or a national coverage decision
that CMS itself coordinates through administrative
processes. The latter was employed by CMS recently
through the conduct of an evidence review for coverage
consideration of pharmacogenomic testing of genes
associated with the biotransformation of warfarin, a
powerful anticoagulant. In May 2009, after extensive
review, CMS made a decision that denied coverage for
routine warfarin pharmacogenomic testing as their find-
ings indicated that clinical utility had not been demon-
strated. CMS went further to outline parameters for
future studies that they would consider supporting under
a “coverage with evidence development” process. This
process allows for the reimbursement of tests if done as
part of a randomized clinical trial where utility can be
assessed. To date, the alignment of evidence needs for
pharmacogenomic tests to meet clinical validity and util-
ity have not been mapped sufficiently for clinical stud-
ies to meet the regulatory needs of FDA and CMS.
Further work in advancing the application of pharma-
cogenomics in medical practice could benefit from most
strategic alignment of evidence needs and resources to
support these studies. 
The perspective of personal utility of genomic informa-
tion has opened a door for new business opportunities
in consumer health services. In 2008, several new direct-
to-consumer services were launched, providing relatively
low-cost genomic analysis and interpretation capabili-
ties to the public, without a physician order. 23andMe,
Knome, deCODEme and Navigenics are among the
companies offer comprehensive genomic analysis and
interpretation to consumers via a Web-based linkage.
These services provide health information to patients
about various personal traits (including behavioral ten-
dencies) and risk assessment probabilities. The genomic
tests in these cases are performed in CLIA-certified lab-
oratories but not FDA approved. Some controversy has
arisen over the validity of these tests and the consistency
of analysis across platforms and databases. Furthermore,
there is concern that none of the genomic information
provided is directly medically actionable. Other genetic
testing services focused on specific genetic mutations
and their associations to neurologic and psychiatric con-
ditions using data developed from GWAS studies have
arisen, including those predicting likelihood of autism
spectrum disorders, and suicidal ideation related to
SSRIs. Due to the lack of substantive clinical trials show-
ing evidence to support these claims and the potential to
cause patient confusion about the interpretation of the
results, these tests have largely been controversial.
30
Among the issues frequently mentioned about the con-
sumer genomics services are the variation in reference
data populations used by the different services account-
ing for different interpretations of risk for the same
patient, oversight of the clinical laboratory measure-
ments through CLIA, and transparency of the use of the
consumer information by the service providers. 
Federal Trade Commission authorities are also playing
a role in assessing unscrupulous marketing tactics by
some companies of tests with unsubstantiated claims of
benefit. Despite the uncertainty, these trends indicate
several factors. Some segments of the consumer base are
interested in potential genetic risks and may use this
information to guide lifestyle and behaviors in their own
health care. Moreover, the interest in consumer genomic
services demonstrates some level of consumer empow-
erment and self-determinism that now permeates other
segments of health care through social networking and
community engagement. How these early experiences in
commercial sector genomic services relate to future
applications is unclear. The likelihood is, however, that
armed with risk information, consumers will seek more
insights from health care providers to guide them in the
use of this information. Most health care providers, how-
ever, are poorly equipped at the present time and access
to medical genetic counselors is sparse, although pro-
vided by some of the current consumer services. 
Conclusions
Overall, the impact of genomic technologies on the
understanding of disease and environment interactions
has been substantial. To translate these advances into
health care as personalized medicine will require sub-
stantial innovation in a systems redesign yielding trans-
formative changes in the values, priorities, and roles of
all participants. Building on information policies in
research, we can anticipate that personalized medicine,
in the context of health care reform, will need to address
some key areas. Molecular diagnostics, for example, are
likely to be required to have higher levels of trans-
parency of supporting data, and confirmatory evidence
that meaningful therapeutic selection decisions can be
made on the basis of the information they provide. Some
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lishing a clinical research framework for evidence devel-
opment in testing the applications of molecular diag-
nostics. Achieving this will almost certainly require more
collaborative interactions between public and private
sectors. 
The attributes of potential cost savings through the
reduction of adverse events and avoidance of using ther-
apeutics when patients will experience no benefit will
need substantive clinical evidence to support coverage
and reimbursement policies. Application of genomic
analysis in risk determination and behavioral and pre-
ventive interventions requires substantially more
research to achieve the most beneficial applications of
scare resources. Furthermore, there will likely be a
greater role for government-sponsored or public-private
collaborations to support prospective and comparative
trials to evaluate the contributions of genomic-based
diagnostic tests. Improvements in cost accounting
throughout health care will be required to demonstrate
the evidence that supports early detection and preven-
tion strategies yield relevant health outcome benefits.
Efforts to identify key data needs to assess clinical util-
ity and cost-effectiveness of molecular diagnostics over-
all will help refine innovation goals for clinical applica-
tion of genomics, and provide innovators with more
specific targets for their research and development
investments. Finally, substantial needs exist for educa-
tion and training of health care providers across many
disciplines to understand the patient care objectives of
personalized medicine. If the course of these develop-
ments is focused on patient care and quality improve-
ment processes, the future contributions of personalized
medicine to patient care will be substantial. ❏
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Perspectivas estratégicas en los nacientes 
caminos de la medicina personalizada
Los notables avances en el conocimiento funda-
mental acerca de las bases biológicas de la enfer-
medad y los avances técnicos en los métodos para
evaluar la información genómica han conducido al
sistema de asistencia sanitaria a las puertas de la
medicina personalizada. Ahora es posible conside-
rar la aplicación estratégica de la información
genómica para que el manejo del paciente resulte
predecible, prioritario y preventivo, y se permita la
participación del paciente en las decisiones médi-
cas. La evidencia inicial de esta transición tiene
algunas características particulares en cuanto a que
las innovaciones alteran las prácticas de la asisten-
cia sanitaria existentes. Se presenta una evaluación
de las modificaciones que están en proceso para
permitir que este nuevo concepto de atención sani-
taria en los Estados Unidos aumente la precisión y
la calidad de la atención a través de innovaciones
dirigidas a propuestas individualizadas para la
toma de decisiones médicas. Será necesario consi-
derar una amplia gama de posturas de políticas
públicas para las empresas prestadoras de atención
sanitaria para que ajusten las promesas de esta
nueva ciencia y tecnología para el beneficio de los
pacientes.   
Perspectives stratégiques dans la voie de la
médecine personnalisée
Des avancées notables dans les connaissances fon-
damentales des bases biologiques des maladies et
des progrès techniques dans les méthodes d’éva-
luation de l’information génomique ont permis de
faire évoluer le système de santé au seuil de la
médecine personnalisée. Il est désormais possible
d’utiliser des applications stratégiques de l’infor-
mation génomique pour guider la prise en charge
du patient, afin qu’elle soit prédictive, préemptive,
et préventive, et qu’elle permette la participation
de celui-ci aux décisions médicales. Cette transition
s’est illustrée de manière précoce par des innova-
tions qui tranchaient avec les pratiques soignantes
existantes. Nous examinons ici les modifications
nécessaires à l’émergence de ce nouveau concept
de soins aux États-Unis afin d’améliorer la précision
et la qualité des soins par des innovations visant à
individualiser la prise de décision médicale. Adapter
cette nouvelle science prometteuse et la technolo-
gie pour le bien des patients nécessitera d’envisa-
ger une grande variété de positions dans l’élabora-
tion de la politique des pouvoirs publics au service
de la santé.
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